Author: admin

  • What Is a Phage?

    What Is a Phage?

    Read time: 4 Minutes.

    If you’ve never heard of a phage before, you’re not alone. The word “Bacteriophage” (or “phage”, for short) comes from the words “bacteria” and the greek word “Phagein” meaning “to eat”. That’s exactly what they do to bacteria. Phages are the most abundant entities on our planet. In fact, if you stacked every living thing on top of each other to make one tower, and stacked every phage in a second tower, they would be approximately the same height. How tall would this tower be? It would extend to the moon and beyond. Unlike the viruses that cause the common cold or flu, phages only attack and kill bacteria and are not capable of recognising human cells. 

    Besides from being found everywhere, phages may hold the key to one of the biggest threats that modern healthcare faces. Antibiotic resistance. Alexander Fleming, credited with the discovery of antibiotics, was the first to mention the term resistance. Just as every life form grows and evolves to overcome the stresses of surviving on planet earth, so too do bacteria. As they are exposed to antibiotics more and more frequently, they are able to learn, adapt, and overcome. This has led to the birth of new kinds of diseases, often referred to as “superbugs”. Diseases that modern medicine cannot cure. In a high profile review from 2014, it was estimated that 10 million people worldwide could die every year as a direct result of antibiotic resistance. (Note: there are various complications when it comes to these calculations, so take this with a pinch of salt. Click here for more) in 2019, superbugs killed more people than malaria or HIV/AIDS.

    So, how can phages fight these seemingly impossible odds?

    If you’ve ever seen the Apollo 11 spacecraft landing on the moon, you already know what a phage looks like. The “legs” of the phage land on the bacterial cell, and recognise proteins on the surface. These proteins are very specific. A phage will often only attack one species of bacteria. Once a phage has landed, and has recognised its target, the next stage can begin. Just as Neil Armstrong emerged from the lunar lander, the phage also releases its own cargo. DNA. Drilling in to the bacterial surface, it injects DNA into the bacterial cell. The DNA provides instructions, a blueprint, of how to make more phages. Tricked by the foreign DNA, the bacteria becomes a phage factory. It builds more and more microscopic spacecraft until there is no more room inside the cell. As the pressure builds, the surface of the bacterial cell bursts, releasing hundreds more phages into the environment, ready to find more bacteria to eat. 

    Not only do phages have the astonishing ability to recognise superbugs, their ability to tell the difference between target and non-target bacteria means that they leave all of the good bacteria in our gut alone. 

    But it gets even cooler, and a lot more complicated. we can use phages to reverse superbugs back into their weaker form, so that they can be killed by antibiotics once again. Imagine a bacteria has infected a patient. The doctor will give them antibiotics. Some bacteria will die, but others may adapt to be immune to the antibiotic. They could do this by building a miniature pump, to remove the antibiotic and avoid harm. As the infection grows, eventually all of the bacteria learn how to pump the antibiotics out. As quicky as that, we now have a superbug on our hands.

    Now imagine we find a phage with special legs that recognise bacteria with pumps. Suddenly, bacteria with pumps are killed. In response, the bacteria try to overcome this attack by destroying all of their pumps, in an effort not to be recognised by our phage. the bacteria are now vulnerable to the antibiotic once again. 

    The San Diego Rescue: A Bacteriophage success story.

    This approach to treating superbugs has already been used. Dr Steffanie Strathdee found a bacteriophage for her gravely ill husband after a holiday to Egypt turned into a fight against superbugs. Surviving sepsis multiple times, and going into a coma, Dr Strathdee and a team of scientists brought her husband, Tom, back from the grip of this deadly disease after just 3 days of treatment where all antibiotics had failed. I had the pleasure if interviewing Dr Strathdee myself as part of a campaign to redesign the UK’s approach to “last resort” medicine.

    Read the full story here

  • Unlocking the Power of Phages

    Unlocking the Power of Phages

    Imagine a treatment that can precisely target harmful bacteria without damaging the good ones your body needs. That’s exactly what bacteriophages – or simply “phages” – can do.

    Phages are naturally occurring viruses that infect and destroy bacteria. They’re the most common organisms on Earth, found in soil, water, and even inside our bodies. Each type of phage is a specialist, evolved to attack only certain bacterial strains. This makes them remarkably precise compared to antibiotics, which often wipe out helpful bacteria along with harmful ones.

    Phage therapy isn’t new. In fact, it’s been used for over a century in parts of Eastern Europe and the former Soviet Union. However, it fell out of favour in the West after antibiotics became widely available. Today, with antibiotic resistance on the rise, scientists are rediscovering phages as a powerful ally in the fight against dangerous infections.

    When bacteria evolve to resist antibiotics, they can cause infections that are difficult – or even impossible – to treat. The World Health Organization warns that antimicrobial resistance could become one of the biggest global health threats of our time. Phages offer a potential solution. They can be matched to the exact bacterial strain causing an infection and, if needed, adapted as the bacteria change.

    Modern phage therapy is being explored for everything from wound care and lung infections to food safety and agriculture. With advances in genomics and biotechnology, it’s now possible to find, test, and prepare phages faster than ever before.

    Phages aren’t here to replace antibiotics entirely, but to complement them – giving doctors a new tool in their arsenal. In a world running out of options, these microscopic bacterial hunters could help tip the balance back in our favour.

  • Current Challenges and Barriers

    Current Challenges and Barriers

    Read time: 5 minutes

    After the discovery of antibiotics, the western world focussed it’s attention on these “miracle drugs”, without appropriate consideration for the future challenges of resistance which we face today. Phages, viruses that infect bacteria whilst leaving human cells alone, are self replicating. This means that they build copies of themselves within the bacterial cell. This is problematic when it comes to clinical trials in the UK.

    1: Clinical trials

    To ensure maximum safety for the public, clinical trials rely on strict safety standards. Scientists refer to these standards as “good manufacturing practices” or “GMP”. One of which is the dose of a medicine used in the trial. However, if a medicine is able to make more of itself within the patient, scientists have little control over the number of phages in the patient’s body after the phages are given. As well as other barriers, legal and economic, phages remain limited to pre-clinical trials.

    However, this does not mean that the UK has not seen successes relating to phage therapy. Under the use of “compassionate medicine” in the UK, a patient can receive an experimental treatment when all other options have been exhausted, and is likely to die without medical intervention. Whilst these cases are time critical, and infections in these patients are well established, there have been successes where phage therapy has brought patients out of the firm grip of superbugs.

    Isabelle’s Story

    Isabelle Carnell-Holdaway, a teenager at the time living in the UK, was taken into hospital with a severe infection. After all antibiotics failed, they turned to the use of compassionate medicine for help.

    Living with cystic fibrosis meant that her lungs contained excessive levels of mucus, a breeding ground for harmful superbugs to hide. Such diseases can’t be cured with antibiotics. After a lung transplant, she required immunosuppressant drugs. These drugs are used to prevent a patient’s immune system from attacking the transplanted lungs, but at the same time, weaken the immune system from attack by superbugs. After becoming critically ill, Scientists set to work, and found 3 phages which were able to attack her infection (pictured above). The scientists then modified the DNA in these phages to make them even more effective against Isabelle’s infection. You can read the full paper here. Phage therapy brought her infection under control within weeks. The BBC reported on her case in 2019.

    2: Lack of investment

    There is a difficult cycle created when a medicine is stuck in pre-clinical trials. Researchers require investment to develop Phage medicine closer to GMP standards, yet investors want evidence that phage therapy works, in the form of clinical trials. So far, phages have only been used in highly complex, time critical and life-threatening diseases. Trials are essential to prove that phage therapy works in regular infections. This creates an uneven playing field when antibiotics are used in everyday infections, yet phage therapy is a last resort for the dangerously ill.

    “the recent webinar series led by the World Health Organisation in collaboration with the Global AMR Research and Development hub, highlighted that phage therapy receives only ∼2% of public and philanthropic funding for AMR research, even though many projects target high-priority bacterial pathogens”

    Find the full story here

    Communicating complex scientific concepts to investors Is important. And has remained a significant barrier between scientists and investors in the development of new drugs. Investment in new antibiotics has fallen due to the high cost of development, and the rapid emergence of resistant superbugs that render these expensive drugs ineffective. Also, a patient only takes antibiotics for a few weeks, until the infection has cleared. Therefore, large pharmaceutical take the economically wise choice to invest in drugs that people need all the time such as insulin for diabetes, statins to control cholesterol, and so on.

    I have written a short post on my LinkedIn about attracting investors, you can read it here

    3. Manufacturing Phages

    Whilst current research is promising, scientists need to continue to research into the potential risk of side effects, as is the case with any new drug. If you’ve read my article on “What is a phage”, you will already know that phages turn the bacterial cell into a phage factory. Whilst this is great for patients, it means that scientists have to make phages within a sample of bacteria taken from the patient. This means that as well as the phages, we also make harmful toxins, and debris produced by bursting bacterial cells. This all needs to be removed before we can administer a phage to a patient. However, scientists now have tools to make (and modify) phages without needing bacterial cells. These “cell free” systems are a key advancement in phage manufacturing.

    If you’ve ever heard of Mr Potato head, a popular childhood toy from the movie “Toy Story” loved my many millennials, cell free systems can work in the same way. We can modify phage DNA to change the properties of the “legs” or “head” of the phage to make it more effective at locating harmful bacteria. switching out or combining the parts of many different phages to create more powerful ones to fight superbugs.

    What does the future hold?

    In my opinion, Phage Therapy is the most promising tool we have to fight antibiotic resistance. Not to replace antibiotics, but to work with them in combination. Through campaigns to UK parliament, investors and the public, we can raise awareness of this crucial tool and boost the UKs position in the landscape of phage research. Our colleagues around the world are making the most of the opportunities provided by phage therapy, social and economic. If we act now, the UK can secure its own place and benefit from the global community fighting against superbugs.